The purpose of this study is to assess the rate of sustained virological response (SVR) 12
weeks after 8-week oral treatment with grazoprevir 100mg/elbasvir 50mg (MRK-combo) in
patients with acute hepatitis C genotype1 or 4.
We will connect you to the doctor responsible for this trial and help you get more information.
Locations near you
Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Full eligibility criteria for NCT02886624
Ages eligible for Study
18 Years and older
Genders eligible for Study
Accepts Healthy Volunteers
Adult ≥18 years.
A recent acute HCV infection [defined by (i) detectable HCV RNA within 6 months after a negative HCV RNA or HCV serology test OR (ii) detectable HCV RNA and acute clinical hepatitis within 5 months prior to screening visit (ALT ≥250 IU/L with normal ALT within the preceding 8 months OR ALT ≥500 IU/L with either no measured ALT or with abnormal ALT within the preceding 8 months)] or reinfection [defined by documented de novo infection after prior clearance post-treatment (defined by one negative HCV RNA
≥6 months after end of treatment) or spontaneously (defined by two negative HCV RNA a minimum of 6 months apart OR documented infection with a new viral strain, confirmed by phylogenetic or genotypic analysis)] within 5 months prior screening OR (iii) patients having reported a risk factor for HCV contamination (traumatic sexual intercourse, intranasal, rectal or intravenous drug use) ≥6 months AND presenting a negative HCV RNA or HCV serology test within 12 months.
Infection with HCV genotype 1 or 4 (confirmed at screening visit or by using a previous biological test performed 1 to 4 weeks before week 0).
Plasma HCV-RNA ≥ 1000 IU/mL (confirmed at screening visit or by using a previous biological test performed 1 to 4 weeks before week 0).
Confirmed HIV infection (only for HIV co-infected patients).
Without HIV treatment or with an authorized stable HIV treatment for at least two weeks (only for HIV co-infected patients).
Body weight ≥40 kg and ≤125 kg.
Female patients with child-bearing potential and their heterosexual partners must use adequate contraception from the date of screening until 30 days after administration of the last dose of study drug. Male participants must agree to consistently and correctly use a condom, while their female partner must use adequate contraception from the date of screening until 30 days after administration of the last dose of study drug.
Informed and signed consent.
Patients with Health insurance (Sécurité Sociale or Couverture Médicale Universelle).
Opportunistic infections (stage C), active or occurred within 6 months prior to baseline.
Primary HIV infection.
Co-infection with Hepatitis B virus (HBsAg-positive) without appropriate treatment
(TDF or TAF) for at least 2 weeks.
Confirmed cirrhosis (before acute HCV diagnosis).
Any other causes of acute hepatitis.
Pregnant or breast-feeding women.
Liver transplant recipients.
Patients with a history of non-adherence, who will be at risk of being unable to respect the study follow-up timetable.
Patients participating in another clinical trial (with an experimental treatment) or within an exclusion period of a previous clinical trial at screening.
Patients under legal gardianship or incarcerated.
Hemaglobulin <10 g/dL (female) or <11g/dL (male).
Platelet count <50,000/mm3.
Neutrophil count < 750/mm3.
Other antiretroviral drugs than those allowed in the study.
Contra-indications to grazoprevir and/or elbasvir or to any of the excipients listed in the summary of the product characteristics.
Contra-indicated treatment likely to interfere with the study drugs as listed in the summary of the product characteristics.
All locations for NCT02886624
CHU de Lyon
Lyon, France, 69317
CHU de Nice
Nice, France, 06200
Paris, France, 75012
Hôpital La Pitié-Salpêtrière
Paris, France, 75013
Paris, France, 75018
Paris, France, 75020
Trial results for NCT02886624
Participant Flow: Overall Study
87 / 89
Completed / Started
Serious Adverse Events
3 / 60
Affected / At Risk
Other Adverse Events
23 / 30
Affected / At Risk
View full eligibility
Tris trial is registered with FDA with number: NCT02886624. The sponsor of the trial is Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba and it is looking for 30 volunteers for the current phase.
Official trial title: Short Duration Therapy of Acute Hepatitis C Genotypes 1 or 4: Efficacy and Tolerability of Grazoprevir 100mg/Elbasvir 50mg During 8 Weeks
1What's a trial
4Get in touch
What's a trial
Not sure you're well informed about clinical trials? Learn more about their benefits, risks and other important details.
Enter your details like condition, age, gender and other preferences and we will show you a list of all relevant clinical trials.
Review the summary of the selected clinical trial and all the locations near you in order to see if it's of interest to you.
Get in touch
You've found an interesting trial? We'll need a bit more information about you so we can connect you to the doctor in charge.
Some people want to consult their doctor before considering participation in a clinical trial. This is absolutely normal as your doctor should know your medical history and should be able to advise you. If you want you can easily share the information for this trial with your doctor by clicking on the button below.